DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?Jason A. Roberts, Juan Carlos Montejo, Sanjoy K. Paul et al.|Clinical Infectious Diseases|2014Cited by 1.1k
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trialPatrick N. A. Harris, David L. Paterson, Emma S. McBryde et al.|Trials|2015Cited by 73
Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based studyDunya Tomic, Dianna J. Magliano, Jedidiah I Morton et al.|The Lancet Diabetes & Endocrinology|2022Cited by 72
Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapyDianne Stephens, Marta Ulldemolins, Xin Liu et al.|Intensive Care Medicine|2025Cited by 11